BRAF and carcinoma: The NCCN and ATA guidelines suggest dabrafenib plus trametinib for BRAF V600 mutated carcinoma, larotrectinib or entrectinib if NTRK gene fusion is positive and pralsetinib or selpercatinib for RET-fusion positive ATC [3, 8].